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Abstract  
Lymphomas are cancers that originate in the lymphatic system. Despite the 
heterogeneity, lymphomas are characterized by the deregulation of the p53-signaling 
pathway. This study describes a systems-wide network analysis of the key mal-
functioning p53-centered network of interactions involved in lymphoma pathogenesis 
through integration of transcriptomic and proteomic data. 
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Abbreviations: 
N3a:  Nutlin-3a  
wt p53:  wild-type p53 
MDM2:  Μurine double minute 2  
HL:  Hodgkin lymphoma  
MCL:  Mantle cell lymphoma   
ALCL:  Anaplastic large cell lymphoma   
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Lymphomas constitute a 
heterogeneous type of haematological 
cancer derived from lymphocytes in 
the lymphatic system, with high 
diversity in both clinical and biological 
terms (Jaffe et al., 2008). One of the 
major characteristics of this blood 
cancer is the deregulation of wild type 
(wt) p53-dependent signaling 
pathways. P53 is a transcription factor 
involved in various cellular functions, 
such as cell cycle, apoptosis and DNA 
repair pathways that maintain cellular 
integrity and defense against cancer. 
P53 deregulation is frequently 
attributed to the cessation of wt p53-
functionality by overexpressed 
modifiers, such as MDM2 (p53's main 
negative regulator) (Fahraeus and 
Olivares-Illana, 2014). MDM2 
interacts with the wt p53 and promotes 
its ubuquitin-mediated degradation 
(Fahraeus and Olivares-Illana, 2014) 
(Figure 1A). Nutlin-3a (N3a), a small 
molecule and a MDM2-antagonist with 
considerable promise in clinical trials, 
has proven to efficiently re-activate 
non-functional wt p53 in lymphomas, 
demonstrating anti-lymphoma effect 
exhibited by cell cycle arrest and 
apoptosis (Drakos et al., 2009, Drakos 
et al., 2011) (Figure 1A).  
Our aim is to understand lymphoma’s 
pathobiology and progression under 
the prism of a systemic approach and 
by focusing on the identification of the 
key mal-functioning p53-centered 
network of protein-protein interactions. 
The current brief report describes a 
network-based analysis and integration 
of data generated at two different 
levels: proteome and transcriptome of 
three lymphoma cell lines (Hodgkin 
lymphoma (HL), anaplastic large cell 
lymphoma (ALCL) and mantle cell 
lymphoma (MCL)), before and after 
the effect of N3a treatment.  
Geared towards our goal, microarray 
transcriptomic and mass spectrometry-
based proteomic datasets were 
generated that enabled the 
development of network-based 
integrated analysis of the effect of 
N3a-treatment on three model 
lymphoma cell lines (HL, ALCL and 
MCL) (Figure 1B). The integrative 
analysis of lymphoma transcriptomics 
and proteomics data was based on 
unpublished work of Dr Konstantina 
Psatha. As a first step in our analysis, 
the identified and relatively quantified 
transcripts and proteins in the N3a-
treated cells were statistically tested 
against the untreated ones and the 
differentially expressed transcripts and 
proteins were defined. The statistical 
inference was applied both on the 
proteomic and transcriptomic 
quantitation values, and the resulted 
data were merged into a final list, 
creating a unified reference dataset. 
Next, we sought to investigate the 
functional roles of the differentially 
expressed transcripts and proteins by 
analyzing the protein-protein 
interaction networks in each 
lymphoma subtype, based on previous 
knowledge available in curated 
protein-protein interaction databases. 
This led us to the underlying protein-
protein interactions, delineating 
specific and overlapping molecular 
signatures among the different 
lymphoma subtypes. We employed 
two distinct network clustering 
approaches, the “Hypothesis Free” and 
the “Targeted”. In the “Hypothesis 
free” approach, the Markov Cluster 
Algorithm in Cytoscape was applied in 
the initial total network, using the 
default parameters. Markov Cluster 
Algorithm organized the network into 
different number of distinct protein 
clusters, and from this, the cluster 
containing p53 protein was chosen for 
further functional analysis. The 
“Targeted” approach used sequentially 
two algorithms: first the MCODE in 
direct mode, and then the Markov 
Cluster Algorithm on the resulted 
Aristotle Biomedical Journal, Vol 1, No 1 e-ISSN: 2653-9748 
 
99 
 
Figure 1: Integrated in silico analysis of –omic data generated from Nutlin-3a (N3a) treated 
lymphoma cell lines. 
A. The p53–MDM2 autoregulatory feedback loop governs p53 amounts. Overexpression of 
MDM2 in human cancer, e.g., gene amplification of MDM2, targets p53 for ubiquitin-
dependent protelytic degradation to disable the p53 network. Nutlin-3a complexes with 
MDM2 and inhibits its interaction with p53 
B. Bioinformatics workflow of intergration of transcriptomic and proteomic data that were 
generated from three lymphoma subtypes (ALCL, HL, MCL) which were treated with Nutlin-
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3a (N3a). Differentially expressed genes were statistically inferred after comparing the 
untreated with the N3a-treated cells. Related protein-protein interaction (PPIs) sub-networks 
were retrieved from STRING database via Cytoscape platform. Network clustering analysis 
and functional/pathway enrichment analysis was performed on the specific PPI networks per 
lymphoma subtype. 
network, in which protein interactions 
around key proteins were examined. 
Analysis and visualization of 
differentially expressed transcript and 
protein networks was achieved using 
specific network clustering plugins and 
algorithms for Cytoscape (Shannon et 
al., 2003). A comparison of pathway 
and Gene Ontology enrichment 
information deriving from different 
data sources and analyses methods, 
identified and implicated many key 
protein and network modules in the 
three lymphoma subtypes. The 
detected abnormalities suggest 
potential directional changes and 
molecular signatures for each cell line, 
underlying the differential 
corresponding clinical outcome. 
Our systems biology point of view 
explored the regulatory pathways and 
protein interaction networks affecting 
multiple cellular processes in the 
lymphoma pathophysiology. Although 
the two analyses showed a very low 
degree of overlap, regarding the 
number of common proteins, 
functional analysis revealed high 
overlap in biological processes 
dominating the p53 interactome every 
time, confirming the validity of global 
transcriptomic and proteomic profiling 
in revealing already reported proteins 
and pathways, along with novel ones. 
Cell cycle, apoptosis, p53 signaling 
pathway were among the pathways 
validated by our pipeline as having 
altered activity upon N3a treatment, in 
all three lymphoma subtypes. Protein 
transport and folding, as well as carbon 
metabolism appeared to be also 
affected in the presence of N3a. Taking 
into consideration the resulting data, 
both developed workflows hold great 
potential for unraveling new biological 
insights, thus fostering an in depth 
understanding of a system under study. 
The potential impact of such holistic 
approaches encourages the notion that 
molecular identification of unique and 
common characteristics between 
different lymphoma entities and other 
diseases, may lead future research to 
the development of new diagnostic, 
prognostic and/or therapeutic schemes, 
promoting new drug discovery and/or 
drug repurposing. 
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